Independent surgical validation of the new prostate cancer grade-grouping system.

Abstract

OBJECTIVE To report the independent prognostic impact of the new prostate cancer grade-grouping system in a large external validation cohort of patients treated with radical prostatectomy (RP). PATIENTS AND METHODS Between 1994 and 2013, 3 694 consecutive men were treated with RP at a single institution. To investigate the performance of and validate the grade-grouping system, biochemical recurrence-free survival (bRFS) rates were assessed using Kaplan-Meier tests, Cox-regression modelling, and discriminatory comparison analyses. Separate analyses were performed based on biopsy and RP grade. RESULTS The median follow-up was 52.7 months. The 5-year actuarial bRFS for biopsy grade groups 1-5 were 94.2%, 89.2%, 73.1%, 63.1%, and 54.7%, respectively (P < 0.001). Similarly, the 5-year actuarial bRFS based on RP grade groups was 96.1%, 93.0%, 74.0%, 64.4%, and 49.9% for grade groups 1-5, respectively (P < 0.001). The adjusted hazard ratios for bRFS relative to biopsy grade group 1 were 1.98, 4.20, 5.57, and 9.32 for groups 2, 3, 4, and 5, respectively (P < 0.001), and for RP grade groups were 2.09, 5.27, 5.86, and 10.42 (P < 0.001). The five-grade-group system had a higher prognostic discrimination compared with the commonly used three-tier system (Gleason score 6 vs 7 vs 8-10). CONCLUSIONS In an independent surgical cohort, we have validated the prognostic benefit of the new prostate cancer grade-grouping system for bRFS, and shown that the benefit is maintained after adjusting for important clinicopathological variables. The greater predictive accuracy of the new system will improve risk stratification in the clinical setting and aid in patient counselling.

DOI: 10.1111/bju.13488
05010020162017
Citations per Year

Citation Velocity: 25

Averaging 25 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Spratt2016IndependentSV, title={Independent surgical validation of the new prostate cancer grade-grouping system.}, author={Daniel E Spratt and Adam I Cole and Ganesh S. Palapattu and Alon Z. Weizer and William C . Jackson and Jeffrey S. Montgomery and Robert T Dess and Shuang G. Zhao and Jae Y. Lee and Angela Wu and Lakshmi Priya Kunju and Emily Talmich and David C. Miller and Brent K. Hollenbeck and Scott Arthur Tomlins and Felix Yi-Chung Feng and Rohit Mehra and Todd M. Morgan}, journal={BJU international}, year={2016}, volume={118 5}, pages={763-769} }